Citeline, a Norstella company

News. Context. Impact.

In-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries.

Execs On The Move: June 9–13, 2025

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Scrip is an invaluable source of information and insight about key developments in the biopharmaceutical industry. It has produced some of the most detailed reporting about emerging therapeutics in our field (the liver disease nonalcoholic steatohepatitis), with crisp perspective on scientific, business and regulatory dynamics.

Chris Frates, VP of Corporate Communications and Patient Advocacy
Madrigal Pharmaceuticals

engaging articles

Engaging Articles

Engaging Articles

Quick to read yet rich in insight, our articles cover a diverse range of topics, delivering sharp, comprehensive analysis in every piece.

contextualized news

Contextualized News

Contextualized News

Go beyond the headlines with our in-depth news coverage, offering background and analysis to ensure you're fully informed on global events.

in-depth reports

Future Trends Analysis

Future Trends Analysis

Discover emerging trends and innovative ideas with our forward-thinking thought-leadership providing actionable insights and visionary perspectives.

thought-provoking podcasts

Thought-Provoking Podcasts

Thought-Provoking Podcasts

Listen to expert-led discussions and analysis through our engaging podcasts, designed to inform and inspire—whenever and wherever you are.

timely features

Timely Features

Timely Features

Stay up-to-date with our regularly updated features, delivering the latest trends, insights, and developments as they unfold.

exclusive conference coverage

Exclusive Conference Coverage

Exclusive Conference Coverage

Get insider access to major industry events with our detailed conference coverage, bringing you the latest insights from top leaders and innovators.

7,000+In-Depth Articles

Expert insights delivered throughout the year

500+Executive Interviews

Exclusive perspectives from industry leaders

2,000+In-Depth Analyses

Deep dives into critical issues and trends

500+Interactive Media

Engaging visual, audio and dynamic content

Our Expertise at a Glance

Discover how our dedicated team delivers unparalleled insights through rigorous research and expert analysis.


Citeline Expertise At A Glance
Citeline News and Insights Journalists
60+ Respected Journalists

Our team of over 60 trusted journalists operates across the US, Canada, UK, and Asia, delivering multilingual content.

Human Intelligence Filter
Human Intelligence Filter

Local teams meticulously review industry news, filtering out 50-90% of the noise to highlight key events.

Citeline Conference Coverage
In-Person Meeting Coverage

Our journalists attend key events both in person and virtually, ensuring comprehensive coverage.

Citeline Research
Thorough Research

We analyze regulatory and policy changes, check internal data, consult in-house analysts, review sell-side reports, and interview multiple sources.

Expert Interviews
Expert Interviews

We engage with company executives, clinical/medical KOLs, regulatory agencies, patient advocacy groups, payer organizations, lawyers, and other experts.

Citeline Premium News Coverage
Premium News with Context

Our premium news includes in-depth analysis, insightful interviews, and comprehensive data.

In-Depth Analysis Powered by Citeline Data

Our global journalists leverage Citeline’s advanced analytics platforms to perform comprehensive data analysis and uncover valuable insights.

In Depth Industry Analysis
  • Industry-Leading Market Analysis Tools: Comprehensive commercial, clinical, and regulatory insights.
  • Real-Time Data Trends: Up-to-the-minute data for the latest industry developments.
  • AI-Driven Solutions: Innovative technology accelerating drug development and delivery to patients.
  • Custom Insights with Ask-the-Analyst: Tailored answers and analysis to address your specific questions.

These powerful tools deliver a wealth of information—from detailed industry reports to real-time data trends—enabling reporting that sets us apart from the rest.

Citeline app
Download App

Expert Analysis Across The Decades

With a rich history and commitment to excellence our seasoned journalists have consistently provided crucial industry insights, reflecting years of dedicated expertise.

Expert Analysis Across The Decades
2003
Generics Bulletin

News and Expert Analysis on Generics and Biosimilars

1981
In Vivo

Strategic Analysis for Medtech and Pharma Leaders

1980
HBW Insight

News and Expert Analysis on the Healthcare Industry

1975
Medtech Insight

News and Expert Analysis for Medtech Decision Makers

1972
Scrip

Pharma News and Expert Analysis for Commercial Decision Makers

1939
Pink Sheet

News and Expert Analysis on Pharma Policy and Regulation

1906
US FDA

Beginnings of
today's FDA


Karen Coleman

Karen Coleman

Executive Director,
News and Insights

Ian Haydock

Ian Haydock

Editor-in-Chief,
APAC

Matt Hobbs

Nielsen Hobbs

Editor-in-Chief,
Pink Sheet

Eleanor Malone

Eleanor Malone

Editor-in-Chief,
Commercial Insights

Andrea Charles

Andrea Charles

Vice President
Custom Content